We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Spotlight on Ustekinumab in Moderate To Severe Plaque Psoriasis.
- Authors
Croxtall, Jamie D.
- Abstract
Ustekinumab (StelaraTM) is a human monoclonal antibody that binds to the p40 subunit common to both interleukin (IL)-12 and IL-23. It is indicated in the US for use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In the EU, it is indicated for those who failed to respond to, have a contraindication to, or are intolerant of other systemic therapies or phototherapy. In well designed, randomized clinical trials, regimens of subcutaneous ustekinumab 45 or 90 mg provided a rapid and durable improvement in Psoriasis Area and Severity Index scores for patients with moderate to severe plaque psoriasis. Treatment with ustekinumab 45 or 90 mg also improved healthrelated quality-of-life scores from baseline. More limited data indicate that ustekinumab also improves the symptoms of arthritis in patients with plaque psoriasis and psoriatic arthritis. Subcutaneous ustekinumab was generally well tolerated in clinical trials; most adverse events were mild in intensity and did not require dosage adjustment. A pooled analysis of clinical trial data indicated no specific patterns of infection for recipients of ustekinumab and that infection rates remained stable following cumulative exposure to the agent. Thus, subcutaneous ustekinumab provides an effective and well tolerated alternative for the symptomatic treatment of patients with moderate to severe plaque psoriasis.
- Subjects
THERAPEUTIC use of monoclonal antibodies; MONOCLONAL antibodies; PHARMACY information services; PSORIASIS; SEVERITY of illness index
- Publication
American Journal of Clinical Dermatology, 2012, Vol 13, Issue 2, p135
- ISSN
1175-0561
- Publication type
Article
- DOI
10.2165/11208650-000000000-00000